Beam Therapeutics
About
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
- Cambridge,Massachusetts,United States
- 501 - 1000
- https://beamtx.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $260M
- Industries
- Biotechnology,Genetics,Medical,Therapeutics
- Founded date
- Jan 1, 2017
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
- Stock Symbol
- nasdaq:BEAM
- Legal Name
- Beam Therapeutics, Inc.
Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 19, 2021 | Post-IPO Equity | $260M | 5 | — | — | Detail |
| Feb 11, 2020 | Post-IPO Equity | $207M | — | — | — | Detail |
| Feb 5, 2020 | IPO | $178M | — | — | — | Detail |
| Mar 6, 2019 | Series B | $135M | 8 | — | — | Detail |
| May 14, 2018 | Series A | $87M | 3 |
ARCH Venture Partners
F-Prime Capital
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Casdin Capital
|
— | Post-IPO Equity |
Cormorant Asset Management
|
— | Post-IPO Equity |
Farallon Capital Management
|
— | Post-IPO Equity |
Perceptive Advisors
|
— | Post-IPO Equity |
|
|
— | Post-IPO Equity |
Altitude Life Science Ventures
|
— | Series B |
|
ARCH Venture Partners
|
— | Series B |
Eight Roads Ventures
|
— | Series B |
|
F-Prime Capital
|
— | Series B |
GV
|
— | Series B |
Employee Profiles
Acquisition
Beam Therapeutics has acquired 1 organizations. Their most recent acquisition was Guide Therapeutics on Feb 23, 2021. They acquired Guide Therapeutics for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Feb 23, 2021
|
Biotechnology | acquisition | — | Detail |
